- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.04. | Reviva Pharmaceuticals FY Non-GAAP EPS of -$1.65 beats by $0.01 | 2 | Seeking Alpha | ||
| 15.04. | Reviva reports FDA acceptance of 4-week RECOVER-2 study for its schizophrenia treatment | 1 | Seeking Alpha | ||
| 15.04. | Reviva Pharmaceuticals: Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia | 300 | GlobeNewswire (Europe) |
- FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA)... ► Artikel lesen | |
| 15.04. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 15.04. | Reviva Pharmaceuticals: Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights | 402 | GlobeNewswire (Europe) | - RECOVER-1 Phase 3 global trial successfully met all primary and secondary endpoints with statistically significant reductions across all major symptom domains in schizophrenia - - Initiation of... ► Artikel lesen | |
| 15.04. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.04. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 4 | SEC Filings | ||
| 26.03. | Reviva Pharmaceuticals: Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting | 9 | GlobeNewswire (USA) | ||
| 11.03. | Reviva Pharmaceuticals: Reviva to Present at the UBS Virtual CNS Day | 5 | GlobeNewswire (USA) | ||
| 20.02. | Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference | 1 | GlobeNewswire (USA) | ||
| 02.02. | Reviva Pharmaceuticals files for $200M mixed securities shelf | 4 | Seeking Alpha | ||
| 25.01. | Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference | 3 | GlobeNewswire (USA) | ||
| 10.01. | Reviva Pharmaceuticals: Reviva to Present at Webull LIVE! Healthcare Webinar on January 17 | 578 | ACCESSWIRE | CUPERTINO, CA / ACCESSWIRE / January 10, 2024 / Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to... ► Artikel lesen | |
| 20.12.23 | Italy's distressed assets and NPEs weekly round-up. News from Reviva and more | 5 | BeBeez | ||
| 11.12.23 | Reviva Pharmaceuticals: Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum | 2 | GlobeNewswire (USA) | ||
| 07.12.23 | AbbVie - Cerevel M&A deal lifts Reviva, Karuna | 15 | Seeking Alpha | ||
| 07.12.23 | VTGN, CERE and RVPH are among pre market gainers | 3 | Seeking Alpha | ||
| 30.11.23 | Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference | 2 | GlobeNewswire (USA) | ||
| 20.11.23 | Reviva Pharmaceuticals raises $30 million for CNS drug development | 2 | Investing.com | ||
| 20.11.23 | Reviva Pharmaceuticals: Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | 258 | GlobeNewswire (Europe) | CUPERTINO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that... ► Artikel lesen |
Seite:
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRONOS GROUP | 2,478 | +2,14 % | Cronos Group Inc. to Hold Virtual 2024 Annual Meeting of Shareholders | ||
| GREEN THUMB INDUSTRIES | 11,590 | +0,70 % | Green Thumb Industries Inc: Green Thumb to open Rise Dispensary Wesley Chapel | ||
| ASTRIA THERAPEUTICS | 9,000 | +7,14 % | Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 0,169 | +5,31 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase | ||
| ORAMED PHARMACEUTICALS | 2,141 | -7,28 % | Oramed Pharmaceuticals Inc.: Oramed Letter to Shareholders | Initiating Phase 3 oral insulin trial in the United States under a new protocol
JV with Chinese Partner, HTIT
Scilex Senior Secured Note
PeriTech Asset Purchase & Strategic Out-licensing
NEW... ► Artikel lesen | |
| CASSAVA SCIENCES | 20,540 | -1,53 % | Cassava Sciences, Inc.: Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials | An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 13,925 | +2,31 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024 | ||
| AURINIA PHARMACEUTICALS | 4,607 | +0,50 % | Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value | ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today provided an update on its 2023 fourth quarter and full year... ► Artikel lesen | |
| ROCKET LAB USA | 3,510 | -0,28 % | How Rocket Lab Outgrew Billionaire Elon Musk's Space Company in Q1 | ||
| KIORA PHARMACEUTICALS | 0,413 | -3,17 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study | Encinitas, California--(Newsfile Corp. - April 11, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) has received grant funding from the Choroideremia Research Foundation (CRF) in support of validating... ► Artikel lesen | |
| AGILE THERAPEUTICS | 0,580 | -3,69 % | Agile Therapeutics, Inc.: Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update | Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility... ► Artikel lesen | |
| LIPOCINE | 4,690 | +3,76 % | Lipocine Inc. - 8-K, Current Report | ||
| BOIRON | 34,150 | +1,49 % | BOIRON: Outlook 2023 - Communication calendar 2024 | The Board of Directors of Laboratoires BOIRON met on 19 December 2023, under the chairmanship of Mr Thierry Boiron.
At this meeting, the Board reviewed the latest business and earnings forecasts... ► Artikel lesen | |
| GUARDION HEALTH SCIENCES | 7,550 | +1,34 % | Guardion Health Sciences, Inc.: Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023 | Viactiv® Product Line Generated Net Revenues of Approximately $11.9 Million for the Year Ended December 31, 2023, an Increase of Approximately 12% as Compared to the Year Ended December 31, 2022 HOUSTON... ► Artikel lesen | |
| ALLERGY THERAPEUTICS | 0,030 | 0,00 % | XFRA HHU: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
Das Unternehmen REVIVA PHARMACEUTICALS HOLDINGS INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,010 (+0,34 %) liegt der Kurs bei 2,990 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
